178 related articles for article (PubMed ID: 32702842)
41. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.
O'Brien MM; Taub JW; Chang MN; Massey GV; Stine KC; Raimondi SC; Becton D; Ravindranath Y; Dahl GV;
J Clin Oncol; 2008 Jan; 26(3):414-20. PubMed ID: 18202418
[TBL] [Abstract][Full Text] [Related]
42. Late mortality and morbidity among long-term leukemia survivors with Down syndrome: A nationwide population-based cohort study.
Vonasek J; Asdahl P; Heyman M; Källén K; Hasle H
Pediatr Blood Cancer; 2018 Sep; 65(9):e27249. PubMed ID: 29797653
[TBL] [Abstract][Full Text] [Related]
43. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee.
Zhang MJ; Hoelzer D; Horowitz MM; Gale RP; Messerer D; Klein JP; Löffler H; Sobocinski KA; Thiel E; Weisdorf DJ
Ann Intern Med; 1995 Sep; 123(6):428-31. PubMed ID: 7639442
[TBL] [Abstract][Full Text] [Related]
44. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
[TBL] [Abstract][Full Text] [Related]
45. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
46. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
47. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
[TBL] [Abstract][Full Text] [Related]
48. Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group.
Goto H; Inukai T; Inoue H; Ogawa C; Fukushima T; Yabe M; Kikuchi A; Koike K; Fukushima K; Isoyama K; Saito T; Ohara A; Hanada R; Iwamoto J; Hotta N; Nagatoshi Y; Okamura J; Tsuchida M
Int J Hematol; 2011 Feb; 93(2):192-198. PubMed ID: 21286878
[TBL] [Abstract][Full Text] [Related]
49. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.
Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L
J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483
[TBL] [Abstract][Full Text] [Related]
50. Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia.
Ceppi F; Stephens D; den Hollander BS; Krueger J; Whitlock J; Sung L; Hitzler J
Pediatr Blood Cancer; 2016 Nov; 63(11):1949-53. PubMed ID: 27399585
[TBL] [Abstract][Full Text] [Related]
51. Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI.
Wheeler KA; Richards SM; Bailey CC; Gibson B; Hann IM; Hill FG; Chessells JM
Blood; 2000 Oct; 96(7):2412-8. PubMed ID: 11001892
[TBL] [Abstract][Full Text] [Related]
52. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
53. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
Kojima S; Sako M; Kato K; Hosoi G; Sato T; Ohara A; Koike K; Okimoto Y; Nishimura S; Akiyama Y; Yoshikawa T; Ishii E; Okamura J; Yazaki M; Hayashi Y; Eguchi M; Tsukimoto I; Ueda K
Leukemia; 2000 May; 14(5):786-91. PubMed ID: 10803507
[TBL] [Abstract][Full Text] [Related]
54. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.
Matloub Y; Rabin KR; Ji L; Devidas M; Hitzler J; Xu X; Bostrom BC; Stork LC; Winick N; Gastier-Foster JM; Heerema NA; Stonerock E; Carroll WL; Hunger SP; Gaynon PS
Blood Adv; 2019 Jun; 3(11):1647-1656. PubMed ID: 31160295
[TBL] [Abstract][Full Text] [Related]
55. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
56. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
[TBL] [Abstract][Full Text] [Related]
57. Induction failure in acute lymphoblastic leukemia of childhood.
Silverman LB; Gelber RD; Young ML; Dalton VK; Barr RD; Sallan SE
Cancer; 1999 Mar; 85(6):1395-404. PubMed ID: 10189148
[TBL] [Abstract][Full Text] [Related]
58. [Leukemia and malnutrition. II. The magnitude of maintenance chemotherapy as a prognostic factor in the survival of patients with standard-risk acute lymphoblastic leukemia].
Lobato-Mendizábal E; Ruiz-Argüelles GJ
Rev Invest Clin; 1990; 42(2):81-7. PubMed ID: 2267453
[TBL] [Abstract][Full Text] [Related]
59. Philadelphia chromosome-positive acute lymphoblastic leukemia and Down syndrome.
Tamaura M; Iwasaki F; Yokosuka T; Fukuda K; Hamonoue S; Goto H
Pediatr Int; 2016 Aug; 58(8):794-7. PubMed ID: 27325175
[TBL] [Abstract][Full Text] [Related]
60. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
